pms-conjugated estrogens c.s.d. tablet
pharmascience inc - conjugated estrogens - tablet - 0.3mg - conjugated estrogens 0.3mg - estrogens
pms-conjugated estrogens c.s.d. tablet
pharmascience inc - conjugated estrogens - tablet - 0.9mg - conjugated estrogens 0.9mg - estrogens
premarin conjugated estrogens 0.625mg tablet blister pack
pfizer australia pty ltd - conjugated estrogens, quantity: 0.625 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; carnauba wax; sucrose; hypromellose; lactose monohydrate; macrogol 400; hyprolose; calcium phosphate; powdered cellulose; titanium dioxide; propylene glycol; purified water; isopropyl alcohol; allura red ac aluminium lake; indigo carmine aluminium lake - oestrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. 1 premarin is indicated as replacement therapy for oestrogen deficiency states associated with climacteric manifested by: a) moderate to severe vasomotor symptoms associated with oestrogen deficiency in natural and surgical menopause (sweating, hot flushes). periodic re-evaluation with a view to short term treatment is recommended. b) atrophic vaginitis. when prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. there is no evidence that oestrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. 2. premarin is indicated for the prevention of postmenopausal osteoporosis in select patients. when prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of premarin should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. (see precautions and dosage and administration). 3. hypoestrogenic states e.g. female hypogonadism, primary ovarian failure or female castration. see boxed warning, particularly when considering premarin for long-term usage.
premarin 0.625mg tablets
pfizer ltd - conjugated oestrogens - oral tablet - 625microgram
premarin 1.25mg tablets
pfizer ltd - conjugated oestrogens - oral tablet - 1.25mg
premarin 0.3mg tablets
pfizer ltd - conjugated oestrogens - oral tablet - 300microgram
premarin tablet 0.625mg
pfizer (malaysia) sdn. bhd. - oestrogens,conjugated -
premarin 0.3 tablet
pfizer (malaysia) sdn. bhd. - oestrogens,conjugated -
premarin vaginal cream 0.625mgg
pfizer (malaysia) sdn. bhd. - oestrogens,conjugated -
premarin 1.25 mg prolonged-release tablets
pfizer healthcare ireland - conjugated estrogens - prolonged-release tablet - 1.25 milligram(s) - natural and semisynthetic estrogens, plain; conjugated estrogens